Physical Exercise Versus Rosiglitazone in CAD and Prediabetes
Primary Purpose
Impaired Glucose Tolerance
Status
Completed
Phase
Phase 4
Locations
Study Type
Interventional
Intervention
rosiglitazone
physical exercise
control
Sponsored by
About this trial
This is an interventional treatment trial for Impaired Glucose Tolerance
Eligibility Criteria
Inclusion Criteria:
- impaired fasting glucose or impaired glucose tolerance
- angiographic evidence of coronary artery disease
Exclusion Criteria:
- diabetes mellitus type I or II
- preexisting antidiabetic medication
- unstable angina
- indication for coronary bypass surgery
- significant left main disease
- myocardial infarction within preceding 3 months
- ejection fraction < 40%
- significant heart valve disease
- severe metabolic disorders
- severe disorders in lipoprotein metabolism
- thyroid disorders
- alcohol or drug abuse
- pregnancy
- participation in another trial
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm Type
Experimental
Active Comparator
No Intervention
Arm Label
1
2
3
Arm Description
physical exercise
control
Outcomes
Primary Outcome Measures
between-group difference in flow-mediated dilation of the brachial artery
Secondary Outcome Measures
relative effects of treatment on parameters of - glucose metabolism - inflammatory plasma markers - markers of endothelial function - cellular markers in muscle and fat biopsies
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT00675740
Brief Title
Physical Exercise Versus Rosiglitazone in CAD and Prediabetes
Official Title
Effects of Physical Exercise Versus Rosiglitazone on Endothelial Function in Coronary Artery Disease Patients With Prediabetes
Study Type
Interventional
2. Study Status
Record Verification Date
January 2010
Overall Recruitment Status
Completed
Study Start Date
January 2004 (undefined)
Primary Completion Date
February 2007 (Actual)
Study Completion Date
February 2007 (Actual)
3. Sponsor/Collaborators
Name of the Sponsor
University of Leipzig
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The aim of this study is to prospectively assess the relative benefits of either treatment with rosiglitazone or physical exercise on endothelial function in patients with impaired fasting glucose or impaired glucose tolerance and coronary artery disease (CAD).
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Impaired Glucose Tolerance
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
Outcomes Assessor
Allocation
Randomized
Enrollment
45 (Actual)
8. Arms, Groups, and Interventions
Arm Title
1
Arm Type
Experimental
Arm Title
2
Arm Type
Active Comparator
Arm Description
physical exercise
Arm Title
3
Arm Type
No Intervention
Arm Description
control
Intervention Type
Drug
Intervention Name(s)
rosiglitazone
Other Intervention Name(s)
Avandia (GlaxoSmithKline)
Intervention Description
tablets 4 mg daily
Intervention Type
Behavioral
Intervention Name(s)
physical exercise
Intervention Description
stationary bike 5-6 times a week
Intervention Type
Other
Intervention Name(s)
control
Intervention Description
control without intervention
Primary Outcome Measure Information:
Title
between-group difference in flow-mediated dilation of the brachial artery
Time Frame
6 months
Secondary Outcome Measure Information:
Title
relative effects of treatment on parameters of - glucose metabolism - inflammatory plasma markers - markers of endothelial function - cellular markers in muscle and fat biopsies
Time Frame
6 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
35 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
impaired fasting glucose or impaired glucose tolerance
angiographic evidence of coronary artery disease
Exclusion Criteria:
diabetes mellitus type I or II
preexisting antidiabetic medication
unstable angina
indication for coronary bypass surgery
significant left main disease
myocardial infarction within preceding 3 months
ejection fraction < 40%
significant heart valve disease
severe metabolic disorders
severe disorders in lipoprotein metabolism
thyroid disorders
alcohol or drug abuse
pregnancy
participation in another trial
12. IPD Sharing Statement
Learn more about this trial
Physical Exercise Versus Rosiglitazone in CAD and Prediabetes
We'll reach out to this number within 24 hrs